Skip to main content
Mural Oncology PLC logo

Mural Oncology PLC — Investor Relations & Filings

Ticker · MURA ISIN · IE000LK2BOB4 BUD Professional, scientific and technical activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2025-05-19 M&A Activity
Country IE Ireland
Listing BUD MURA

About Mural Oncology PLC

https://www.muraloncology.com/

Mural Oncology PLC is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer treatment. The company leverages its proprietary protein engineering platform to create novel, cytokine-based therapies. Its primary focus is on developing first- and best-in-class drugs for difficult-to-treat tumor types where other immunotherapies, such as checkpoint inhibitors, have not been effective. The company's pipeline is led by nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy. This candidate is being evaluated in clinical trials for various advanced solid tumors, including platinum-resistant ovarian cancer and advanced melanoma, addressing areas of high unmet medical need.

Recent filings

Filing Released Lang Actions
Mural Oncology Announces Number of Relevant Securities in Issue
M&A Activity Classification · 95% confidence The document is an official announcement by Mural Oncology plc regarding its issued share capital and outstanding equity instruments, specifically issued in accordance with Rule 2.12 of the Irish Takeover Rules. This type of disclosure is a standard requirement during an 'offer period' in M&A activity to inform the market of the company's capital structure. While it relates to M&A, it is not a merger agreement or a takeover bid itself, but rather a regulatory disclosure required by the Irish Takeover Panel. Given the specific context of takeover rules and capital disclosure, it fits best under M&A Activity (TAR) as it pertains to the regulatory requirements surrounding a potential takeover.
2025-05-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-14 English
FORM 8.1(a) & (b) - Mural Oncology plc
M&A Activity Classification · 95% confidence The document is an 'Opening Position Disclosure' filed under the Irish Takeover Panel Act, 1997. This type of filing is specifically required during M&A activities to disclose the interests and short positions of an offeror or offeree. While it relates to M&A, it is a specific regulatory disclosure form (Form 8.1) rather than a general M&A announcement (TAR). Given the specific nature of takeover-related disclosures and the lack of a more precise category for 'Takeover Panel Disclosures', it falls under the 'M&A Activity' (TAR) category as it pertains directly to the takeover process.
2025-04-30 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.